Innate Pharma (IPHYF) Current Deferred Revenue (2017 - 2025)

Innate Pharma's Current Deferred Revenue history spans 9 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 399.57% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, up 399.57%, while the annual FY2025 figure was $3.3 million, 393.22% up from the prior year.
  • Current Deferred Revenue reached $3.3 million in Q4 2025 per IPHYF's latest filing, up from $658254.8 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $14.3 million in Q4 2021 to a low of $658254.8 in Q4 2024.
  • Average Current Deferred Revenue over 5 years is $6.2 million, with a median of $6.3 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: tumbled 89.57% in 2024, then surged 399.57% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $14.3 million in 2021, then tumbled by 53.2% to $6.7 million in 2022, then fell by 5.71% to $6.3 million in 2023, then crashed by 89.57% to $658254.8 in 2024, then soared by 399.57% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Current Deferred Revenue are $3.3 million (Q4 2025), $658254.8 (Q4 2024), and $6.3 million (Q4 2023).